Natalya V. Serbina

This study evaluates the in vitro pharmacokinetics and pharmacodynamics of TBAJ-587 and its metabolites against M. tuberculosis, showing their efficacy and binding behavior in different media.

This study determines the minimal effective oral dose of telacebec against M. leprae in a mouse model, finding 20 mg/kg achieves complete bacterial clearance.

This paper evaluates the adjunctive effect of the HO-1 inhibitor stannsoporfin in combination with a novel MDR-TB regimen in a murine model, showing reduced lung bacillary burden but no effect on microbiological relapse.